<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00026078</url>
  </required_header>
  <id_info>
    <org_study_id>GOCS-02-BR-01</org_study_id>
    <secondary_id>CDR0000068969</secondary_id>
    <secondary_id>NCI-V01-1670</secondary_id>
    <nct_id>NCT00026078</nct_id>
  </id_info>
  <brief_title>Docetaxel and Ifosfamide in Treating Women With Metastatic Breast Cancer</brief_title>
  <official_title>Docetaxel (DTX) - Ifosfamide (IFX) As First Line Chemotherapy In Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Oncologico Cooperativo del Sur</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die.

      PURPOSE: Phase II trial to study the effectiveness of docetaxel and ifosfamide in treating
      women who have metastatic breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the efficacy of docetaxel and ifosfamide as first-line chemotherapy in women
           with metastatic breast cancer.

        -  Determine the response rate and duration of response of patients treated with this
           regimen.

        -  Determine the time to treatment failure and survival of patients treated with this
           regimen.

        -  Determine the toxicity of this regimen in these patients.

        -  Determine the quality of life of patients treated with this regimen.

      OUTLINE: This is a multicenter study.

      Patients receive docetaxel IV over 1 hour on day 1 and ifosfamide IV over 1 hour (beginning 1
      hour after docetaxel infusion) on days 1-3. Treatment continues every 4 weeks in the absence
      of disease progression or unacceptable toxicity.

      Quality of life is assessed at baseline, every month during study, and then every 3 months
      after completion of study.

      Patients are followed every 3 months.

      PROJECTED ACCRUAL: A total of 15-42 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2001</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as assessed by CTC version 2.0</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as assessed by Schipper's Functional Living Index - Cancer</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed metastatic breast cancer

          -  Bidimensionally measurable lesions

               -  The following are not considered measurable:

                    -  Bone lesions

                    -  Leptomeningeal disease

                    -  Ascites

                    -  Pleural/pericardial effusion

                    -  Inflammatory breast disease

                    -  Lymphangitis cutis/pulmonis

          -  Disease progression after hormonal therapy allowed provided at least 1 month since
             last therapeutic manipulation

          -  No CNS metastases

          -  Hormone receptor status:

               -  Not specified

        PATIENT CHARACTERISTICS:

        Age:

          -  21 to 75

        Sex:

          -  Female

        Menopausal status:

          -  Not specified

        Performance status:

          -  ECOG 0-2 OR

          -  Zubrod 0-2

        Life expectancy:

          -  More than 12 weeks

        Hematopoietic:

          -  WBC at least 4,000/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Hemoglobin at least 11 g/dL

        Hepatic:

          -  Bilirubin no greater than 1.25 times upper limit of normal (ULN)

          -  SGOT no greater than 1.25 times ULN

        Renal:

          -  Creatinine clearance at least 60 mL/min

        Cardiovascular:

          -  No history of congestive heart failure

          -  No myocardial infarction within the past 6 months

          -  No active ischemic heart disease

          -  No uncontrolled hypertension

        Other:

          -  Not pregnant

          -  No other prior or concurrent malignancy except properly treated basal cell skin cancer
             or carcinoma in situ of the cervix

          -  No other medical or psychiatric diseases that would preclude study

          -  No geographical situation that would preclude study

          -  No history of alcohol abuse

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior adjuvant chemotherapy including ifosfamide or docetaxel

          -  No prior systemic chemotherapy for metastatic breast cancer

        Endocrine therapy:

          -  See Disease Characteristics

          -  No concurrent corticoids, gestagens, or androgens unless strictly indicated

        Radiotherapy:

          -  Not specified

        Surgery:

          -  Not specified

        Other:

          -  No concurrent drinks containing caffeine or alcohol
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernardo A. Leone, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Unidad Oncologica Del Neuquen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grupo Oncologico Cooperativo del Sur</name>
      <address>
        <city>Bahia Blanca</city>
        <state>Buenos Aires</state>
        <zip>8000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Eduardo Perez, MD</last_name>
      <phone>54-291-452-5667</phone>
      <email>jperez@criba.edu.ar</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinica Privada Instituto De Medicina Nuclear</name>
      <address>
        <city>Bahia Blanca</city>
        <state>Buenos Aires</state>
        <zip>8000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Omar Romero, MD</last_name>
      <phone>54-291-453-9848</phone>
      <email>gocsbhb@bvconline.com.ar</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Joseph Medical Center</name>
      <address>
        <city>Gonnet</city>
        <state>Buenos Aires</state>
        <zip>1987 MB</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergio Grasso, MD</last_name>
      <phone>54-221-4845088</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanatorio Santa Rosa S.R.L.</name>
      <address>
        <city>Santa Rosa</city>
        <state>La Pampa</state>
        <zip>6300</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo Heriberto Ortiz, MD</last_name>
      <phone>54-2954-29-715</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>C.R I O.</name>
      <address>
        <city>Mar del Plata</city>
        <zip>7600</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo L. Rodriguez, MD</last_name>
      <phone>54-223-479-3283</phone>
      <email>ricrodri@copetel.com.ar</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unidad Oncologica Del Neuquen</name>
      <address>
        <city>Neuquen</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernardo A. Leone, MD</last_name>
      <phone>54-299-448-5247</phone>
      <email>bleone@satlink.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Tres Arroyos</name>
      <address>
        <city>Tres Arroyos</city>
        <zip>7500</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Ester Dominguez, MD</last_name>
      <phone>0983-33450</phone>
      <email>medominquez@3net.com.ar</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Medico Nacional de Occidente</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>4430</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilberto Morgan Villela, MD</last_name>
      <phone>523-641-5081</phone>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Mexico</country>
  </location_countries>
  <verification_date>November 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>August 6, 2013</last_update_submitted>
  <last_update_submitted_qc>August 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2013</last_update_posted>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

